Panitumumab (anti-EGFR)

Name: Panitumumab (anti-EGFR)
Brand: MedChemExpress
SKU: HY-P99041A
Rating: 4.5 (1 reviews)

Cat. No.: HY-P99041A Purity: 98.00%: FAQs
Data Sheet SDS COA

Molarity Calculator

Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer.

For research use only. We do not sell to patients.

Panitumumab (anti-EGFR) Chemical Structure

Size	Price	Stock	Quantity
1 mg	USD 220	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 650	In-stock	Estimated Time of Arrival: December 31
10 mg		Get quote
50 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

View All Isoforms

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Panitumumab (2 nM-2 μM, 3 h) (anti-EGFR) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells^[3].
? Panitumumab (0-200 μg/mL, 48 h) (anti-EGFR) inhibits the proliferation of DLD-1 cells^[4].
? Panitumumab (80 μg/mL, 24 h) (anti-EGFR) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:	EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells
Concentration:	2, 20, 200, 2000 nM
Incubation Time:	3 h
Result:	Inhibited ligand-induced autophosphorylation of EGFR.

In Vivo

Panitumumab (25, 100, or 500 μg/mouse, i.p., twice a week) (anti-EGFR) inhibits tumor growth in NCI-H1975 and NCI-H1650 xenografts, compared with control (P < 0.0003)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCI-H1975 and NCI-H1650 xenografts^[3]
Dosage:	25, 100, or 500 μg/mouse
Administration:	Intraperitoneal injection (i.p.), twice a week
Result:	Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation. Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.

Clinical Trial

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Panitumumab (anti-EGFR)]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Purity: 98.00%

Select Batch:

Data Sheet (261 KB) SDS (251 KB)

COA (291 KB)

Handling Instructions (2659 KB)

References

[1]. Giannopoulou E, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82. PMID: 20044619.. . . [Content Brief]

[2]. Yu Jo Chua, et al. Panitumumab. Drugs Today (Barc). 2006 Nov;42(11):711-9. [Content Brief]

[3]. Stefan Stremitzer, et al. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 2014 Jun;13(6):843-51. [Content Brief]

[4]. Daniel J. Freeman, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther (2009) 8 (6): 1536–1546. [Content Brief]

[5]. Efstathia Giannopoulou, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82.